DTTC with Caregiver Training for Childhood Apraxia of Speech
(DTTC Trial)
Trial Summary
The trial does not specify whether participants need to stop taking their current medications. However, children with ADHD can participate if they can attend sessions with medication and/or strategies.
Research shows that DTTC, a motor-based treatment, can improve speech intelligibility in children with Childhood Apraxia of Speech. Additionally, training parents to use DTTC at home has been found effective in providing more intensive treatment, especially in rural areas.
12345The research articles provided do not contain specific safety data for Dynamic Temporal and Tactile Cueing (DTTC) in humans. They focus on the effectiveness and implementation of the treatment for childhood apraxia of speech, but do not address safety concerns.
13567DTTC (Dynamic Temporal and Tactile Cueing) is unique because it focuses on motor-based intervention, using specific timing and touch cues to help children with childhood apraxia of speech improve their speech intelligibility. This approach is different from other treatments that may not emphasize the same level of motor planning and tactile feedback.
12458Eligibility Criteria
This trial is for children aged between 2 years and 5 months to 7 years and 11 months with a primary diagnosis of Childhood Apraxia of Speech (CAS) who speak English as their main language. Kids with autism, global developmental delay, Down syndrome, or severe hearing or visual impairments can't join. Those already receiving speech treatment elsewhere are also excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-Treatment
Caregivers complete an online self-guided educational module about CAS and DTTC
Treatment
Participants receive DTTC treatment 2x/week for 8 weeks with home practice 3x/week
Follow-up
Home practice continues at a higher frequency (6x/week) to monitor treatment outcomes
Participant Groups
Dynamic Temporal and Tactile Cueing (DTTC) is already approved in United States, Canada, European Union for the following indications:
- Childhood Apraxia of Speech (CAS)
- Childhood Apraxia of Speech (CAS)
- Childhood Apraxia of Speech (CAS)